Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

RXRG001

PreclinicalBiologic

RRiboX Therapeutics Ltd.

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Radiation-Induced Xerostomia and HyposalivationRecruiting

Radiation-Induced Xerostomia and HyposalivationPreclinical

Recruiting

Timeline

Expected Milestones

Q3 2027

PreclinicalRecruiting

Radiation-Induced Xerostomia and Hyposalivation

NCT06714253

Clinical

Trials by Indication[1]

Radiation-Induced Xerostomia and Hyposalivation1 trial

A Phase I/IIa, Dose Escalation Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of Intraductal Administration of RXRG001 to Parotid Gland(s) in Adults With Radiation-Induced Xerostomia and Hyposalivation

Recruiting·RRiboX Therapeutics Ltd.·Preclinical·NCT06714253·42 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for RXRG001. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — RXRG001 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for RXRG001. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — RiboX Therapeutics Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: RRiboX Therapeutics Ltd.

Related News